作者
Phanindra KM Venukadasula, Benjamin Y Owusu, Namita Bansal, Larry J Ross, Judith V Hobrath, Donghui Bao, Jackie W Truss, Murray Stackhouse, Troy E Messick, Lidija Klampfer, Robert A Galemmo Jr
发表日期
2016/2/11
期刊
ACS medicinal chemistry letters
卷号
7
期号
2
页码范围
177-181
出版商
American Chemical Society
简介
In this letter we report first nonpeptide inhibitors of hepatocyte growth factor (HGF) activation. These compounds inhibit the three proteases (matriptase, hepsin, and HGF activator) required for HGF maturation. We show that 6, 8a, 8b, and 8d block activation of fibroblast-derived pro-HGF, thus preventing fibroblast-induced scattering of DU145 prostate cancer cells. Compound 6 (SRI 31215) is very soluble (91 μM) and has excellent microsome stability (human t1/2 = 162 min; mouse t1/2 = 296 min). In mouse 6 has an in vivo t1/2 = 5.8 h following IV administration. The high solubility of 6 and IV t1/2 make this compound a suitable prototype “triplex inhibitor” for the study of the inhibition of HGF activation in vivo.
引用总数
201620172018201920202021202220232024257512111
学术搜索中的文章
PKM Venukadasula, BY Owusu, N Bansal, LJ Ross… - ACS medicinal chemistry letters, 2016